Document is current

Article History

Received: 5 May 2025

Accepted: 2 July 2025

First Online: 23 August 2025

Disclosure

: Judy C. Boughey receives institutional research funding from Eli Lilly, SimBioSys, and Quantum Leap Healthcare, and serves on the Data Safety Monitoring Board for Cairn Surgical. Angela DeMichele reports institutional research funding from Novartis, Pfizer, Genentech, and Neogenomics, and serves as Program Chair for the Scientific Advisory Committee at the American Society for Clinical Oncology. Douglas Yee reports research funding fromNIH/NCI P30 CA077598, P01 CA234228-01, and R01CA251600; consulting fees from Martell Diagnostics; and honoraria and travel for speaking at the International Breast Cancer Conference. Nola Hylton reports institutional research funding from the NIH. W. Fraser Symmans reports shares from IONIS Pharmaceuticals and Eiger Biopharmaceuticals; has received consulting fees from AstraZeneca; is a co-founder of and has equity in Delphi Diagnostics; and has issued patents for (1) a method to calculate residual cancer burden, and (2) genomic signature to measure sensitivity to endocrine therapy. Laura van’t Veer is a founding advisor and shareholder of Exai Bio, and is a part-time employee of and owns stock in Agendia. Hope Rugo reports institutional research support from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx, and Greenwich Pharma, and advisory and consulting roles with Chugai, Puma, Sanofi, Napo, and Mylan. MD reports research grants from the NIH/NCI and NIH/NIA, and contracts from the Patient-Centered Outcomes Research Institute. Laura J. Esserman reports participation on the Blue Cross Medical Advisory Panel, and is an uncompensated board member of Quantum Leap Healthcare Collaborative. Rebecca Shatsky reports institutional research funding from OBI Pharmaceuticals, Quantum Leap Healthcare Collaborative, AstraZeneca, and Gilead; serves on the AstraZeneca and Stemline Advisory Boards and the Gilead Speaker’s Bureau; and reports a consultancy role with Quantum Leap Healthcare Collaborative. Claudine Isaacs reports institutional research funding from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, BMS, Genentech, Novartis, and Regeneron; consultancy roles with AstraZeneca, Genentech, Gilead, ION, Merck, Medscape, MJH Holdings, Novartis, Pfizer, PUMA, and Seagen; and royalties from Wolters Kluwer (UptoDate) and McGraw Hill (Goodman and Gillman). Julie Van Hassel, Katrina Dimitroff, Christina Yau, Rita Mukhtar, Velle Ladores, Marissa M. Howard-McNatt, Nora Jaskowiak, Jane Perlmutter, Henry Kuerer, Anne M. Wallace, Nicolas Prionas, Jennifer Tseng, Chantal R. Reyna, Neil Taunk, Susan Kesmodel, Marie C. Lee, Jana Fox, Mara A. Piltin, Julia Tchou, Cletus A. Arciero, Lauren M. Postlewait, Candice Sauder, and Roshni Rao declare no competing interests that may be relevant to the contents of this study.